Private Medical Cannabis vs NHS: Differences Explained

The NHS and Medical Cannabis: The Reality

• The NHS can prescribe cannabis-based medicines but does so extremely rarely in practice
• NICE guidelines currently recommend Epidyolex (CBD for childhood epilepsy) and Sativex (nabiximols for MS spasticity) on the NHS
• For all other conditions — including chronic pain, PTSD and anxiety — NHS specialist prescribing is very limited and inconsistent by region
• As of the most recently available data, the vast majority of UK medical cannabis prescriptions are private

The gap between legal availability and NHS access is one of the most discussed issues in UK medical cannabis policy. Legalisation created the legal framework, but clinical commissioning and NICE guidance have not yet caught up for most indications.

How Private Cannabis Prescribing Works

• Private specialist clinics operate independently of the NHS and are not subject to CCG funding restrictions
• Patients self-refer or obtain a GP letter and pay for consultations and medication directly
• Private prescription fees and medication costs are fully the patient’s responsibility
• The prescribing standard — GMC-registered specialists, CD prescription forms — is identical to NHS requirements

Private prescribing is not a lower standard of care — it uses the same legal framework and professional standards as NHS prescribing. The difference is funding, not quality.

Cost Comparison

• NHS prescription charge (for licensed products like Sativex): £9.90 per prescription item (standard NHS charge)
• Private prescription for flower or oil: typically £150–£400+ per month in medication costs alone
• Patients with medical exemptions from NHS charges (e.g. chronic conditions) would pay nothing for an NHS-prescribed CBMP
• The financial impact of private prescribing is significant — patient advocacy groups have long called for broader NHS commissioning

The cost disparity between NHS and private access is a significant equity issue. Patients with means can access treatment within days; those reliant on NHS commissioning may wait months or years, or not be offered it at all.

Will NHS Access Improve?

• The NHS Ten Year Plan and evolving NICE guidance may widen commissioning over time
• The Drug Science Project Twenty21 and similar real-world evidence initiatives are generating the data NICE needs
• Patient advocacy organisations including the Medical Cannabis Clinicians Society continue to lobby for expanded access
• Progress is slow but directional — the trajectory is towards broader access, not less

The momentum is in the right direction. As real-world evidence from the thousands of private patients accumulates and is published, the pressure on NICE and NHS commissioners to act will continue to grow.